Display options
Cite
Moimier G, Guy C, Berthoux F, et al. Atteintes rénales graves au cours d'un traitement par anti-inflammatoires non stéroïdiens arylcarboxyliques : bilan d'une enquête nationale de pharmacovigilance. [Not Available]. Therapie. 2006;61(3):255-66doi: 10.2515/therapie:2006035.
Moimier, G., Guy, C., Berthoux, F., Beyens, M. N., Ratrema, M., & Ollagnier, M. (2006). Atteintes rénales graves au cours d'un traitement par anti-inflammatoires non stéroïdiens arylcarboxyliques : bilan d'une enquête nationale de pharmacovigilance. [Not Available]. Therapie, 61(3), 255-66. https://doi.org/10.2515/therapie:2006035
Moimier, Geneviève, et al. "Atteintes rénales graves au cours d'un traitement par anti-inflammatoires non stéroïdiens arylcarboxyliques : bilan d'une enquête nationale de pharmacovigilance." [Not Available]. Therapie vol. 61,3 (2006): 255-66. doi: https://doi.org/10.2515/therapie:2006035
Moimier G, Guy C, Berthoux F, Beyens MN, Ratrema M, Ollagnier M. Atteintes rénales graves au cours d'un traitement par anti-inflammatoires non stéroïdiens arylcarboxyliques : bilan d'une enquête nationale de pharmacovigilance. [Not Available]. Therapie. 2006 May-Jun;61(3):255-66. doi: 10.2515/therapie:2006035. French. PMID: 27393524.
Copy Download .nbib Format: NLM
Share it on

Therapie. 2006 May-Jun;61(3):255-66. doi: 10.2515/therapie:2006035.

[Not Available].

Therapie

[Article in French]
Geneviève Moimier, Claire Guy, François Berthoux, Marie Noëlle Beyens, Martine Ratrema, Michel Ollagnier

Affiliations

  1. Centre Régional de Pharmacovigilance, Hôpital Bellevue, Saint-Étienne, France. Electronic address: [email protected].
  2. Centre Régional de Pharmacovigilance, Hôpital Bellevue, Saint-Étienne, France.
  3. Service de Néphrologie, Hôpital Nord, Saint-Priest-en-Jarez, France.

PMID: 27393524 DOI: 10.2515/therapie:2006035

Abstract

The non-steroidal anti-inflammatory drugs (NSAID) especially the arylcarboxylic, are widely prescribed for their different properties. The renal adverse events are rare but often serious. We have reviewed the French experience for the following eight years period: January 1995 to December 2002. Three hundred and nine cases have been reported to the French Pharmacovigilance system during that period including 275 adults, 29 children and 5 new-born babies. In 247 cases (80%), the presentation was an acute renal failure occuning few days after treatment onset but not always of the prerenal type. Overall 34 patients needed one or more dialysis session; the majority recovered either completely or partially, but nevertheless, we had to deplore 5 deaths. These major renal complications were observed with all available NSAID on the French market, including ibuprofen which was often prescribe as pain-reliever. With this data together with international information, the French Drug Agency decided to modify the summary of products characteristics of these NSAID.

Copyright © 2006 Société Française de Pharmacologie et de Thérapeutique. Publié par Elsevier Masson SAS.

Keywords: AINS; NSAID; arylcarboxylic; arylcarboxyliques; effets indésirables rénaux; pharmacovigilance; renal failure

Publication Types